BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 31011760)

  • 21. The non-interventional BonViva Intravenous Versus Alendronate (VIVA) study: real-world adherence and persistence to medication, efficacy, and safety, in patients with postmenopausal osteoporosis.
    Hadji P; Felsenberg D; Amling M; Hofbauer LC; Kandenwein JA; Kurth A
    Osteoporos Int; 2014 Jan; 25(1):339-47. PubMed ID: 24091594
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High persistence over two years with denosumab among postmenopausal women with osteoporosis in France: A prospective cohort study.
    Briot K; Schott AM; Sanchez JP; Chauny JV; Samama P; Désaméricq G
    Bone; 2021 May; 146():115890. PubMed ID: 33610904
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Fracture risk following intermission of osteoporosis therapy.
    Dennison EM; Cooper C; Kanis JA; Bruyère O; Silverman S; McCloskey E; Abrahamsen B; Prieto-Alhambra D; Ferrari S;
    Osteoporos Int; 2019 Sep; 30(9):1733-1743. PubMed ID: 31175404
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term persistence with anti-osteoporosis drugs after fracture.
    Klop C; Welsing PM; Elders PJ; Overbeek JA; Souverein PC; Burden AM; van Onzenoort HA; Leufkens HG; Bijlsma JW; de Vries F
    Osteoporos Int; 2015 Jun; 26(6):1831-40. PubMed ID: 25822104
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Real-world Management of Women with Postmenopausal Osteoporosis Treated with Denosumab: A Prospective Observational Study in the Czech Republic and Slovakia.
    Růžičková O; Killinger Z; Kasalický P; Hamilton L; Tyl R; Tomková S; Kalouche-Khalil L
    Adv Ther; 2018 Oct; 35(10):1713-1728. PubMed ID: 30191465
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Medication persistence and risk of fracture among female Medicare beneficiaries diagnosed with osteoporosis.
    Liu J; Guo H; Rai P; Pinto L; Barron R
    Osteoporos Int; 2018 Nov; 29(11):2409-2417. PubMed ID: 30022254
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Observations following discontinuation of long-term denosumab therapy.
    McClung MR; Wagman RB; Miller PD; Wang A; Lewiecki EM
    Osteoporos Int; 2017 May; 28(5):1723-1732. PubMed ID: 28144701
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adherence to osteoporosis medications amongst Singaporean patients.
    Cheen MH; Kong MC; Zhang RF; Tee FM; Chandran M
    Osteoporos Int; 2012 Mar; 23(3):1053-60. PubMed ID: 21503813
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Further reductions in nonvertebral fracture rate with long-term denosumab treatment in the FREEDOM open-label extension and influence of hip bone mineral density after 3 years.
    Ferrari S; Adachi JD; Lippuner K; Zapalowski C; Miller PD; Reginster JY; Törring O; Kendler DL; Daizadeh NS; Wang A; O'Malley CD; Wagman RB; Libanati C; Lewiecki EM
    Osteoporos Int; 2015 Dec; 26(12):2763-71. PubMed ID: 26068295
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Two-year persistence and compliance with osteoporosis therapies among postmenopausal women in a commercially insured population in the United States.
    Durden E; Pinto L; Lopez-Gonzalez L; Juneau P; Barron R
    Arch Osteoporos; 2017 Dec; 12(1):22. PubMed ID: 28243883
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study.
    Papapoulos S; Lippuner K; Roux C; Lin CJ; Kendler DL; Lewiecki EM; Brandi ML; Czerwiński E; Franek E; Lakatos P; Mautalen C; Minisola S; Reginster JY; Jensen S; Daizadeh NS; Wang A; Gavin M; Libanati C; Wagman RB; Bone HG
    Osteoporos Int; 2015 Dec; 26(12):2773-83. PubMed ID: 26202488
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The impact of GI events on persistence and adherence to osteoporosis treatment: 3-, 6-, and 12-month findings in the MUSIC-OS study.
    Modi A; Sen S; Adachi JD; Adami S; Cortet B; Cooper AL; Geusens P; Mellström D; Weaver JP; van den Bergh JP; Keown P; Sajjan S
    Osteoporos Int; 2018 Feb; 29(2):329-337. PubMed ID: 29110061
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Persistence with denosumab and zoledronic acid among older women: a population-based cohort study.
    Tremblay É; Perreault S; Dorais M
    Arch Osteoporos; 2016 Dec; 11(1):30. PubMed ID: 27679503
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Persistence with Denosumab in Male Osteoporosis Patients: A Real-World, Non-Interventional Multicenter Study.
    Jeong C; Lee J; Kim J; Ha J; Jo K; Lim Y; Kim MK; Kwon HS; Sohn TS; Song KH; Kang MI; Baek KH
    Endocrinol Metab (Seoul); 2023 Apr; 38(2):260-268. PubMed ID: 37150519
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Severe spontaneous vertebral fractures after denosumab discontinuation: three case reports.
    Aubry-Rozier B; Gonzalez-Rodriguez E; Stoll D; Lamy O
    Osteoporos Int; 2016 May; 27(5):1923-5. PubMed ID: 26510845
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Denosumab treatment lapses, discontinuation, and off-treatment fracture risk: A retrospective study of patients with osteoporosis in a real-world clinical setting.
    Cruchelow KR; Peter ME; Chakrabarti A; Gipson HM; Gregory WT; DeClercq J; Choi L; Tanner SB
    Bone; 2023 Dec; 177():116925. PubMed ID: 37797711
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Real-world effectiveness of osteoporosis treatments in Germany.
    O'Kelly J; Bartsch R; Kossack N; Borchert J; Pignot M; Hadji P
    Arch Osteoporos; 2022 Aug; 17(1):119. PubMed ID: 36044096
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Increased treatment persistence and its determinants in women with osteoporosis with prior fracture compared to those without fracture.
    Jacob L; Dreher M; Kostev K; Hadji P
    Osteoporos Int; 2016 Mar; 27(3):963-969. PubMed ID: 26519418
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Increased fracture risk after discontinuation of anti-osteoporosis medications among hip fracture patients: A population-based cohort study.
    Fu SH; Wang CY; Hung CC; Lee CC; Yang RS; Huang CC; Farn CJ; Lin WH; Chen HM; Hsiao FY; Lin JW; Li CY
    J Intern Med; 2021 Dec; 290(6):1194-1205. PubMed ID: 34237171
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Retrospective evaluation of serum CTX levels after denosumab discontinuation in patients with or without prior exposure to bisphosphonates.
    Uebelhart B; Rizzoli R; Ferrari SL
    Osteoporos Int; 2017 Sep; 28(9):2701-2705. PubMed ID: 28540505
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.